Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cholestene lawsuit

This article was originally published in The Tan Sheet

Executive Summary

Cholestin-maker Pharmanex files civil contempt motion against HPF LLC, alleging the Trevose, Penn.-based firm's marketing of its Cholestene red yeast rice product violates a Utah federal judge's preliminary injunction. Pharmanex asserts HPF has continued to advertise Cholestene in its old trade dress, continued to rely on Cholestin-based studies in advertising, product materials and on the Internet. A hearing on the motion is set for Oct. 12. A trial is tentatively scheduled for November 2000 on Pharmanex's claims that Cholestene packaging is deceptively similar to Cholestin (1"The Tan Sheet" May 10, In Brief)

You may also be interested in...



Cholestene injunction

Salt Lake City, Utah federal court issues preliminary injunction against Prevose, Penn.-based HPF, Inc. in response to a complaint filed by Pharmanex, the Cholestin manufacturer says. Judge Dale Kimball orders that until the case comes to trial, Cholestene may not be marketed in its current packaging. The injunction follows an April 14 suit filed by Pharmanex asserting Cholestene packaging is deceptively similar to that of Cholestin. According to company data, Pharmanex has spent approximately $5 mil. on R&D for its red yeast rice dietary supplement for healthy cholesterol in addition to $1.8 mil. in litigation against FDA to protect the regulatory status of the product

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS090379

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel